

FORM PTO-1390 (Modified) (REV 10-95)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>0018-0993-0 PCT</b>
TRANSMITTAL LETTER TO THE UNITED STATES		DESIGNATED/ELECTED OFFICE (DO/EO/US)		U.S. APPLICATION NO. (IF KNOWN. SEE 37 CFR <b>08/945805</b>
CONCERNING A FILING UNDER 35 U.S.C. 371				PRIORITY DATE CLAIMED <b>12 May 1995, earliest</b>
INTERNATIONAL APPLICATION NO. <b>PCT/JP96/01234</b>	INTERNATIONAL FILING DATE <b>10 May 1996</b>			

## TITLE OF INVENTION

**REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kB**

## APPLICANT(S) FOR DO/EO/US

**Ryuichi MORISHITA, et al**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.  A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a.  is transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  has been transmitted by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7.  A copy of the International Search Report (PCT/ISA/210).
8.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a.  are transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  have been transmitted by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
9.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10.  An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11.  A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 13 to 18 below concern document(s) or information included:**

13.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.  A **FIRST** preliminary amendment.  
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16.  A substitute specification.
17.  A change of power of attorney and/or address letter.
18.  Certificate of Mailing by Express Mail
19.  Other items or information:

**Notice of Priority****PCT/IB/304****PCT/IB/308****Request For Consideration of Documents Cited in International Search Report**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
	PCT/JP96/01234	0018-0993-0 PCT

20. The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

<input type="checkbox"/> Search Report has been prepared by the EPO or JPO .....	\$930.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) .....	\$720.00
<input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....	\$790.00
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	\$1,070.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....	\$98.00

**CALCULATIONS PTO USE ONLY**

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

**\$930.00**

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).

20  30

**\$130.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	26 - 20 =	6	x \$22.00	<b>\$132.00</b>
Independent claims	4 - 3 =	1	x \$82.00	<b>\$82.00</b>

Multiple Dependent Claims (check if applicable).

\$270.00

**TOTAL OF ABOVE CALCULATIONS = \$1,544.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

\$0.00

**SUBTOTAL = \$1,544.00**

Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).

20  30

+ \$0.00

**TOTAL NATIONAL FEE = \$1,544.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

\$0.00

**TOTAL FEES ENCLOSED = \$1,544.00**

Amount to be: refunded	\$
charged	\$

A check in the amount of **\$1,544.00** to cover the above fees is enclosed.

Please charge my Deposit Account No. in the amount of A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.  
Crystal Square Five, Fourth Floor  
1755 Jefferson Davis Highway  
Arlington, Virginia 22202  
United States of America

William E. Beaumont

Telephone Number (703) 413-3008 Registration Number 30,996  
Facsimile Number (703) 413-2220

Norman F. Oblon

NAME

24,618

REGISTRATION NUMBER

November 12, 1997

DATE

41 Rec'd PCT/PTO 12 NOV 1997

REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-κBTECHNICAL FIELD

The present invention relates to the prevention and treatment of various diseases associated with NF-κB which is known to be a regulatory factor in the transcription of cytokines and adhesion factors. More particularly, the invention relates to an NF-κB decoy, a composition comprising said decoy for the therapy and prophylaxis of NF-κB-associated diseases, and a method for said therapy and prophylaxis.

BACKGROUND ART

A variety of diseases including asthma, cancers, heart diseases, autoimmune diseases, and viral infections manifest varying symptoms and signs and yet it has been suggested that either an overexpression or underexpression of one or a few proteins is a major etiologic factor in many cases. Moreover, a variety of transcriptional regulatory factors such as transcription activators and transcription inhibitors are involved in the expression of proteins. NF-κB, a substance known to be one of such transcriptional regulatory factors, is a heterodimer of p65 and p50 proteins. In the cytoplasm, NF-κB is usually present as substance binding with IκB, an inhibition factor, and thereby prevented from migrating into the nucleus.

However, when cell is stimulated by cytokines, ischemia, or reperfusion for whatever reason, I $\kappa$ B is phosphorylated and decomposed so that the NF- $\kappa$ B is activated and penetrates into the nucleus. NF- $\kappa$ B attaches itself to the NF- $\kappa$ B binding site of the chromosome and then promotes transcription of the gene located at downstreams. The gene controlled by NF- $\kappa$ B includes cytokines such as IL-1, IL-6, IL-8, etc. and adhesion factors such as VCAM-1, ICAM-1, etc...

#### DISCLOSURE OF THE INVENTION

Predicting that stimulation of the production of those cytokines and adhesion factors is causative of various morbidities such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia, the inventors of this invention did much research and found that it is a rewarding therapeutic approach to suppress expression of those genes which are activated by NF- $\kappa$ B by administering a decoy of the NF- $\kappa$ B binding site of chromosome, that is to say a compound which specifically antagonizes the binding site of chromosome to which NF- $\kappa$ B is conjugated. The present invention has been developed on the basis of the above finding.

The present invention, therefore, provides a pharmaceutical composition comprising an NF- $\kappa$ B decoy as an active ingredient for the therapy and prophylaxis of various NF- $\kappa$ B-associated diseases and a method for said therapy and prophylaxis.

The diseases in which the therapeutic/prophylactic composition of the invention is indicated are NF- $\kappa$ B-associated diseases, that is to say diseases caused by the unwanted activation of genes under control of the transcriptional regulatory factor NF- $\kappa$ B, and among such diseases can be reckoned ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia. The ischemic disease includes ischemic diseases of organs (e.g. ischemic heart diseases such as myocardial infarction, acute heart failure, chronic heart failure, etc., ischemic brain diseases such as cerebral infarction, and ischemic lung diseases such as pulmonary infarction), aggravation of the prognosis of organ transplantation or organ surgery (e.g. aggravation of the prognosis of heart transplantation, cardiac surgery, kidney transplantation, renal surgery, liver transplantation, hepatic surgery, bone marrow transplantation, skin grafting, corneal transplantation, and lung transplantation),

100-1000-0000-0000-0000-0000

reperfusion disorders, and post-PTCA restenosis. The inflammatory disease mentioned above includes various inflammatory diseases such as nephritis, hepatitis, arthritis, etc., acute renal failure, chronic renal failure, and arteriosclerosis, among other diseases. The autoimmune disease mentioned above includes but is not limited to rheumatism, multiple sclerosis, and Hashimoto's thyroiditis. Particularly the pharmaceutical composition containing the NF-κB decoy according to the present invention as an active ingredient is very suited for the therapy and prophylaxis of reperfusion disorders in ischemic diseases, aggravation of the prognosis of organ transplantation or organ surgery, post-PTCA restenosis, cancer metastasis and invasion, and cachexia such as weight loss following the onset of a cancer.

The NF-κB decoy that can be used in the present invention may be any compound that specifically antagonizes the NF-κB binding site of the chromosome and includes but is not limited to nucleic acids and their analogs. As preferred examples of said NF-κB decoy, there can be mentioned oligonucleotides containing the nucleotide sequence of GGGATTCCC (the sequence from the 8th through the 17th nucleotides from the 5'-end of SEQ ID NO:1 in Sequence Listing) or its complementary sequence,

muteins thereof, and compounds containing any of them within the molecule. The oligonucleotides may be DNAs or RNAs, and may contain modified nucleotides and/or pseudonucleotides. Furthermore, those oligonucleotides, variants thereof, or compounds containing any of them may be single-stranded or double-stranded and linear or cyclic. The variants are those involving mutations such as substitution, addition and/or deletion of any part of the above-mentioned sequence, and mean nucleic acids specifically antagonizing the binding site of chromosome to which NF- $\kappa$ B is conjugated. The more preferred NF- $\kappa$ B decoy includes double-stranded oligonucleotides each containing one or a plurality of the above nucleotide sequence and variants thereof. The oligonucleotide which can be used in the present invention includes oligonucleotides modified so as to be less susceptible to biodegradation, such as those oligonucleotides containing the thiophosphoric diester bond available upon substitution of sulfur for the oxygen of the phosphoric diester moiety (S-oligo) and those oligonucleotides available upon substitution of a methyl phosphate group carrying no electric charge for the phosphoric diester moiety.

Regarding to a technology for producing the NF- $\kappa$ B decoy for use in the present invention, the conventional chemical or

biochemical methods for synthesis can be utilized. When a nucleic acid, for instance, is to be used as the NF- $\kappa$ B decoy, the methods for nucleic acid synthesis which are commonly used in genetic engineering can be employed. For example, the objective decoy oligonucleotide can be directly synthesized on a DNA synthesizer. Or a nucleic acid or its fragments, each synthesized beforehand, can be amplified by PCR or using a cloning vector or the like. Furthermore, the desired nucleic acid can be obtained by such procedures as cleavage with restriction enzymes or the like and/or ligation by means of DNA ligase or the like. In order to obtain a decoy nucleotide which is more stable within cells, the base, sugar or/and phosphoric acid moieties of the nucleic acid may be alkylated, acylated, or otherwise chemically modified.

The pharmaceutical composition containing the NF- $\kappa$ B decoy as an active ingredient according to the present invention is not limited in form only if the active ingredient may be taken up by the cells in the affected site or the cells of the target tissue. Thus, the NF- $\kappa$ B decoy, either alone or in admixture with the common pharmaceutical carrier, can be administered orally, parenterally, topically or externally. The pharmaceutical composition may be provided in liquid dosage

35-2017-02-00000000

forms such as solutions, suspensions, syrups, liposomes, lotions, etc. or in solid dosage forms such as tablets, granules, powders, and capsules. Where necessary, those pharmaceutical compositions may be supplemented with various vehicles, excipients, stabilizers, lubricants, and/or other conventional pharmaceutical additives, such as lactose, citric acid, tartaric acid, stearic acid, magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, and so on.

Particularly when a nucleic acid or a modification product thereof is used as the NF- $\kappa$ B decoy, the preferred dosage form includes those which are generally used in gene therapy, such as liposomes inclusive of membrane fusion liposomes utilizing Sendai virus and liposomes utilizing endocytosis, preparations containing cationic lipids such as Lipofectamine (Life Tech Oriental) or virosomes utilizing a retrovirus vector, adenovirus vector, or the like. Particularly preferred are membrane fusion liposomes.

The structure of such a liposomal preparation may be any of a large unilamellar vesicle (LUV), a multi-lamellar vesicle (MLV), and a small unilamellar vesicle (SUV). The approximate

size of vesicles may range from 200 to 1000 nm for LUV, from 400 to 3500 nm for MLV, and from 20 to 50 nm for SUV but in the case of a membrane fusion liposomal preparation using Sendai virus, for instance, MLV with a vesicular system of 200-1000 nm in diameter is preferably employed.

There is no limitation on the technology for liposome production only if the decoy can be successfully entrapped in vesicles. Thus, such liposomes can be manufactured by the conventional techniques such as the reversed phase evaporation method (Szoka, F., et al: Biochim. Biophys. Acta, Vol. 601 559 (1980)), ether injection method (Deamer, D. W.: Ann. N. Y. Acad. Sci., Vol. 308 250 (1978)), and surfactant method (Brunner, J., et al: Biochim. Biophys. Acta, Vol. 455 322 (1976)), to name but a few examples.

The lipid that can be used for constructing a liposomal structure includes phospholipids, cholesterol and its derivatives, and nitrogen-containing lipids but phospholipids are generally preferred. The phospholipid that can be used includes naturally-occurring phospholipids such as phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol,

50546666  
50546666  
50546666  
50546666  
50546666  
50546666  
50546666  
50546666

phosphatidylethanolamine, phosphatidic acid, cardiolipin, sphingomyelin, egg yolk lecithin, soybean lecithin, lysolecithin, etc., the corresponding phospholipids hydrogenated by the conventional method, and synthetic phospholipids such as dicetyl phosphate, distearoylphosphatidylcholine, dipalmitoylphosphatidyl-choline, dipalmitoylphosphatidylethanolamine, di-palmitoylphosphatidylserine, eleostearoylphosphatidyl-choline, eleostearoylphosphatidylethanolamine, eleostearoylphosphatidylserine, and so on.

The lipids inclusive of phospholipids can be used each alone or in a suitable combination. By using a lipid containing a positively-charged atomic group such as ethanolamine or choline within the molecule, the binding rate of an electrically negative decoy nucleotide can be enhanced. In addition to the principal phospholipid, various compounds such as cholesterol and its derivatives, stearylamine, -tocopherol, etc., which are known as liposome additives, can be added in the manufacture of liposomes.

To the resulting liposomes can be added a membrane fusion promoter such as Sendai virus, inactivated Sendai virus, a

membrane fusion promoting protein purified from Sendai virus, polyethylene glycol, or the like can be added for assisting in the intracellular uptake by the cells at the affected site or of the target tissue.

A typical procedure for the production of pharmaceutical liposomes is now described in detail. The above-mentioned liposome-forming substance as well as cholesterol or the like is dissolved in an organic solvent such as tetrahydrofuran, chloroform, ethanol, or the like. In a suitable vessel, the solvent is distilled off under reduced pressure to leave a film of the liposome-forming substance on the inside wall of the vessel. Then, a buffer containing the NF- $\kappa$ B decoy is added and the mixture is stirred. After optional addition of said membrane fusion promoter, the liposomes are isolated. The liposomes in which the NF- $\kappa$ B decoy has thus been entrapped are suspended in a suitable medium or a lyophilizate thereof is redispersed in a suitable medium for use in therapy. The membrane fusion promoter may be added in the interim period after isolation of the liposomes and before use.

There is no limitation on the decoy content of the pharmaceutical composition containing the NF- $\kappa$ B decoy as an

active ingredient only if the decoy is contained in amounts effective to control NF-κB-associated diseases. Thus, the decoy content can be liberally selected according to the disease to be controlled, the target site, dosage form, and dosage schedule.

The pharmaceutical composition containing the NF-κB decoy as an active ingredient as provided in the above manner can be administered by various methods according to the type of disease and the kind of decoy contained. Taking ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis or invasion, and cachexia as examples, the composition can be infused intravascularly, applied directly to the affected area, injected into the lesion, or administered into the regional blood vessel in the affected region. As a further specific example, when PTCA is performed for infarction of an organ, the pharmaceutical composition can be administered into the local blood vessel concurrently with the operation or pre- and postoperatively. For organ transplantation, the graft material can be previously treated with the composition of the invention. Furthermore, in the treatment of osteoarthritis or rheumatism, the composition can be directly injected into the joint.

The dosage of the NF- $\kappa$ B decoy is selected with reference to the patient's age and other factors, type of disease, the kind of decoy used, etc. but for intravascular, intramuscular, or intraarticular administration, for instance, a unit dose of 10-10,000 nmoles can generally be administered once to a few times daily.

BEST MODE FOR CARRYING OUT THE INVENTION

The following examples are intended to describe the present invention in further detail.

Example 1

Synthesis of an NF- $\kappa$ B decoy (decoy oligonucleotide)

On a DNA synthesizer, an NF- $\kappa$ B decoy oligonucleotide and a scrambled decoy oligonucleotide (an oligonucleotide having the same base composition as the NF- $\kappa$ B decoy oligonucleotide but a randomized sequence), the nucleotide sequences of which are shown below, were respectively synthesized from S-oligonucleotides. Those nucleotides were heated at 80°C for 30 minutes and then allowed to cool to room temperature over 2 hours to provide double-stranded DNAs.

NF- $\kappa$ B decoy oligonucleotide

CCTTGAAGGGATTCCTCC

GGAACTTCCCTAAAGGGAGG

Scrambled decoy oligonucleotide

TTGCCGTACCTGACTTAGCC

AACGGCATGGACTGAATCGG

Example 2

Production of liposomal preparations

Phosphatidylserine, phosphatidylcholine, and cholesterol, provided in a weight ratio of 1:4.8:2 (a total of 10 mg), were dissolved in tetrahydrofuran. Using a rotary evaporator, the tetrahydrofuran was removed from the lipid solution to leave the lipid in the form of a film adherent to the flask wall. To this was added 200 ml of saline (BSS; 139 mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl, pH 7.6) containing the NF- $\kappa$ B decoy oligonucleotide (0.7 mg) prepared in Example 1 and the mixture was stirred and sonicated under the usual conditions to provide a suspension of liposomes containing the NF- $\kappa$ B decoy oligonucleotide. This suspension of liposome vesicles (0.5 ml, lipid content 10 mg) was mixed with purified Sendai virus (Z strain, 10000 hemagglutinating units) exposed to UV radiation

(110 erg/mm<sup>2</sup>/sec) 3 minutes before use and the mixture was made up to 4 ml with BSS. This mixture was held at 4°C for 5 minutes and, then, subjected to gentle shaking at 37°C for 30 minutes. After the Sendai virus not bound to the liposomes was removed by sucrose density gradient centrifugation, the uppermost layer was separated and its concentration was adjusted with BSS to provide a liposomal preparation containing 8 µM NF-κB decoy oligonucleotide as entrapped. A liposomal preparation was similarly produced using the scrambled decoy oligonucleotide of Example 1 in lieu of the NF-κB decoy oligonucleotide.

### Example 3

#### A reperfusion model experiment

##### (1) Method

After 9 ~ 10-week-old SD rats were anesthetized with pentobarbital sodium, a cannula was inserted into the left carotid artery adjacent to the airway and indwelled near the aortic valve of the heart (close to the ostium of the coronary artery). In addition, the trachea was cannulated and the animal was placed on supportive respiration by connecting the tracheal cannula to an artificial respirator. Thereafter, a left intercostal incision was made and the left descending anterior

branch of the rat heart was ligated to produce ischemia. After 30 minutes, the ligating suture was cut to start reperfusion. Immediately thereafter, 1.5 ml/rat of the liposomally entrapped NF-κB decoy nucleotide or scrambled decoy nucleotide prepared in Example 2 was administered via the cannula indwelled close to the ostium of the coronary artery. After the chest was closed, the trachea was also sutured and the animal was kept alive. After 24 hours, the rat was reanesthetized and the heart was enucleated and washed with saline. The ventricle of the rat heart was sliced into six sections which were stained with tetrazolium chloride (TTC). The six sections were respectively photographed and subjected to image analysis. The infarcted area was calculated by means of the following equation.

Infarction rate (%) =

the sum of infarct areas of 6 sections/the sum of areas of 6 sections × 100

Statistical analysis was made by multiple comparison (ANOVA).

## (2) Results

The results are presented in Table 1. In the untreated

control group and the scrambled decoy treatment group, myocardial infarcts were found in approximately equal degrees. In the group given the NF- $\kappa$ B decoy nucleotide, the infarct was suppressed to 19% with a significant difference ( $P<0.01$ ) from the untreated group and the scrambled decoy group.

Table 1

NF- $\kappa$ B decoy nucleotide group	Scrambled decoy group	Untreated group
Myocardial infarct area/ total area		
19 2%	28 1%	28 1%

A similar inhibitory effect was found when the liposomes were administered immediately before induction of infarction.

#### Example 4

##### Inhibition of cancer metastasis

###### (1) Method

To 7-week-old female mice of the C57BL/6 strain,  $1 \times 10^4$  murine reticulum cell sarcoma M5076 cells were administered

B6G040-G05G06G07

intravenously and 24 hours later 0.2 ml (6 nmoles) of an NF- $\kappa$ B decoy nucleotide prepared in the same manner as Example 2 was administered intravenously. A control group received 0.2 ml of saline in the same manner. On day 14 after intravenous administration of M5076, the animal was autopsied and the number of tumor nodules on the surface of the liver was counted under the stereoscopic microscope. Each group consisted of 10 mice. For statistical analyses, Kruskal-Wallis test and Dunnett's multiple comparison were used.

## (2) Results

Whereas the mean number of tumor nodules in the control group was 166 with a median value of 173 (116-198), the NF- $\kappa$ B decoy treatment group showed a mean number of 29 and a median number of 27 (19-54). Thus, between the NF- $\kappa$ B decoy treatment group and the control group, a significant difference was found at the 1% level.

## Example 5

### Inhibition of cachexia

#### (1) Method

Using 7-week-old male BALB/c mice, a 2 mm cubic tumor mass of murine colon cancer line Colon 26 was transplanted

subdermally. Beginning day 7 after transplantation, 0.2 ml (6 nmoles) of the NF- $\kappa$ B decoy or the scrambled decoy was administered into the tumor mass and the body weight and tumor weight were serially determined. The animal was autopsied on day 13 and the epididymal fat and gastrocnemius muscle were isolated and weighed. Furthermore, the wet carcass weight exclusive of all the remaining organs and tumor was determined. The tumor weight was calculated from the major and minor diameters of each tumor mass by means of the following equation.

$$\text{Tumor weight (mg)} = \\ \text{major diameter} \times \text{minor diameter}^2 / 2$$

Each group consisted of 10 mice. Statistical analyses were made by ANOVA in one-way layout and Dunnett's multiple comparison.

## (2) Results

In the tumor-bearing group, growth of the tumor resulted in significant decreases in body weight, epididymal fat weight, gastrocnemius muscle weight, and wet carcass weight. In the NF- $\kappa$ B decoy group, improvements were obtained, amounting to 47% for body weight, 42% for epididymal fat weight, 60% for gastrocnemius weight, and 52% for wet carcass weight. However,

no improvement was found in the scrambled decoy group. There was no definite effect on tumor weight.

#### Sequence Listing

(1) SEQ ID NO:1

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double-stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: synthetic DNA

(iii) SEQUENCE: SEQ ID NO:1

CCTTGAAGGG ATTTCCCTCC

(1) SEQ ID NO:2

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double-stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: synthetic DNA

(iii) SEQUENCE: SEQ ID NO:2

TTGCCGTACC TGACTTAGCC

What is claimed is:

1. A pharmaceutical composition for the therapy and prophylaxis of NF-κB-associated disease which comprises an NF-κB decoy.
2. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.
3. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is an ischemic disease.
4. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.
5. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic heart disease, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA

restenosis.

6. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is a cancer metastasis or invasion or cachexia.

7. A nucleic acid having a nucleotide sequence corresponding to the 8th through 17th nucleotides from the 5' end of the sequence represented by SEQ ID NO:1 in Sequence Listing or a variant thereof.

8. The pharmaceutical composition according to Claim 1 wherein the NF-κB decoy is the nucleic acid defined in Claim 7.

9. A liposomal composition comprising the NF-κB decoy defined in Claim 7.

10. A method for the therapy and prophylaxis of NF-κB-associated disease which comprises administering an effective amount of an NF-κB decoy to a mammal.

11. The method according to Claim 10 wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.

12. The method according to Claim 10 wherein the NF-

DESERVING  
AUGUST 2009

κB-associated disease is an ischemic disease.

13. The method according to Claim 10 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.

14. The method according to Claim 10 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic heart diseases, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA restenosis.

15. The method according to Claim 10 wherein the NF-κB-associated disease is a cancer metastasis or invasion or cachexia.

16. The method according to Claim 10 wherein the NF-κB decoy is the nucleic acid defined in Claim 7.

17. Use of an NF-κB decoy for the therapy and prophylaxis of NF-κB-associated disease.

18. The use according to Claim 17 wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.

19. The use according to Claim 17 wherein the NF-κB-

associated disease is an ischemic disease.

20. The use according to Claim 17 wherein the NF- $\kappa$ B-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.

21. The use according to Claim 17 wherein the NF- $\kappa$ B-associated disease is a reperfusion disorder in ischemic heart diseases, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA restenosis.

22. The use according to Claim 17 wherein the NF- $\kappa$ B-associated disease is a cancer metastasis or invasion or cachexia.

23. The use according to Claim 17 wherein the NF- $\kappa$ B decoy is the nucleic acid defined in Claim 7.

ABSTRACT

Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF- $\kappa$ B is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF- $\kappa$ B, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia.

2025 RELEASE UNDER E.O. 14176

# Declaration, Power Of Attorney and Petition

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

---

## REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-KB

---

the specification of which

- is attached hereto.
- was filed on \_\_\_\_\_ as  
Application Serial No. \_\_\_\_\_  
and amended on \_\_\_\_\_.
- was filed as PCT international application  
Number \_\_\_\_\_ PCT/JP96/01234  
on \_\_\_\_\_ May 10, 1996 \_\_\_\_\_,  
and was amended under PCT Article 19  
on \_\_\_\_\_ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
7/114990	Japan	12/05/95	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
7/285504	Japan	02/11/95	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

We (I) hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status (pending, patented, abandoned)
PCT/JP96/01234	May 10, 1996	

And we (I) hereby appoint: Norman F. Oblon, Registration Number 24,618; Marvin J. Spivak, Registration Number 24,913; C. Irvin McClelland, Registration Number 21,124; Gregory J. Maier, Registration Number 25,599; Arthur I. Neustadt, Registration Number 24,854; Richard D. Kelly, Registration Number 27,757; James D. Hamilton, Registration Number 28,421; Eckhard H. Kuesters, Registration Number 28,870; Robert T. Pous, Registration Number 29,099; Charles L. Gholz, Registration Number 26,395; Vincent J. Sunderdick, Registration Number 29,004; William E. Beaumont, Registration Number 30,996; Steven B. Kelber, Registration Number 30,073; Robert F. Gnuse, Registration Number 27,295; Jean-Paul Lavallee, Registration Number 31,451; Timothy R. Schwartz, Registration Number 32,171; Stephen G. Baxter, Registration Number 32,884; Martin M. Zoltick, Registration Number 35,745; Robert W. Hahl, Registration Number 33,893; Richard L. Treanor, Registration Number 36,379; Steven P. Weihrouch, Registration Number 32,829; John T. Goolkasian, Registration Number 26,142; Marc R. Labgold, Registration Number 34,651; William J. Healey, Registration Number 36,160; Richard L. Chinn, Registration Number 34,305; Steven E. Lipman, Registration Number 30,011; and Jacques M. Dulin, Registration Number 24,067; our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C., whose Post Office Address is: Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

*Ryuichi Morishita*  
NAME OF FIRST ~~XXXX~~ INVENTOR

Signature of Inventor

November 5, 1997

Date

Residence: 2-11-22-502, Miyahara,  
Yodogawa-ku, Osaka-shi,  
OSAKA 532 JAPAN

Citizen of: Japan

Post Office Address: the same as above

Toshio Ogiwara

NAME OF SECOND JOINT INVENTOR




Signature of Inventor

November 5, 1997

Date

Toshiko Sugimoto

NAME OF THIRD JOINT INVENTOR




Signature of Inventor

November 5, 1997

Date

Kazuhiro Maeda

NAME OF FOURTH JOINT INVENTOR



Signature of Inventor

November 5, 1997

Date

Ikuo Kawamura

NAME OF FIFTH JOINT INVENTOR



Signature of Inventor

November 5, 1997

Date

Residence: 2-7-29, Sakuragaoka,

Minoo-shi, OSAKA 562 JAPAN

Citizen of: Japan

Post Office Address:

the same as above

Residence: 33-4-201, Koyamaminamiohno-cho,

Kita-ku, Kyoto-shi, KYOTO 603 JAPAN

Citizen of: Japan

Post Office Address:

the same as above

Residence: 1-7-38, Higashinaka,

Yamatotakada-shi, NARA 635 JAPAN

Citizen of: Japan

Post Office Address:

the same as above

Residence: 2-9-1-715, Higashinakafuri,

Hirakata-shi, OSAKA 573 JAPAN

Citizen of: Japan

Post Office Address:

the same as above

*60*  
Toshiyuki Chiba

NAME OF SIXTH JOINT INVENTOR

*[Signature]*  
Signature of Inventor

November 5, 1997

Date

NAME OF SEVENTH JOINT INVENTOR

Signature of Inventor

Date

NAME OF EIGHTH JOINT INVENTOR

Signature of Inventor

Date

NAME OF NINTH JOINT INVENTOR

Signature of Inventor

Date

Residence: 1-1-503, Nakatsujicho,  
Nara-shi, NARA 630 JAPAN

Citizen of: Japan

Post Office Address: the same as above

Residence:

Citizen of:

Post Office Address:

Residence:

Citizen of:

Post Office Address:


Residence:

Citizen of:

Post Office Address:

# United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



## Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
  - All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".  
Pages \_\_\_\_\_ do not meet these requirements.
  - Papers are not flexible, strong, smooth, non-shiny, durable, and white.
  - Papers are not typewritten or mechanically printed in permanent ink on one side.
  - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
  - Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
  - The drawings or copy of drawings are not suitable for electronic reproduction.
  - All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
  - Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) \_\_\_\_\_ are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) \_\_\_\_\_ are missing.
5. OTHER: NO DRAWINGS